HeyJaredNDVC
NDVC is a newsletter for health and biotech founders. I share insights from the people shaping how healthcare gets built and paid for (policymakers, funders, operators, and strategic partners) so you can make smarter decisions about growth.
- Indexed issues, last 90 days
- 5
- Latest publication
- Aug 31, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest issues
Fund Your Next Milestone Without Raising Venture Capital (opens the original)
Read excerpt
Every year, billions of dollars in non-dilutive capital go to startups through federal and state programs, corporate partnerships, foundations, accelerators, tax credits, and other sources. This capital can fund clinical studies, regulatory work, commercialization, and R&D, helping founders get further before they need to raise again.That’s why we’re bringing together Founders Capital Summit: Fund Your Next Milestone Without Raising Venture Capital, a day of hands-on workshops specifically for h
Clearance Does Not Drive Commercialization (opens the original)
Read excerpt
POV: Your product is in pilot. The doctor used it to catch a signal two other devices missed. The patient survived. You are a hero!The device works. It has users. It is demonstrating real value, literally saving lives.And then … it goes nowhere. The pilot doesn’t convert. You never reach commercialization. What happened?Arvita Tripati saw this one first hand. As our ‘commercialization and value creation whisperer’ at <span
The Capital Flex Playbook: 5 Moves Every Founder Should Know Before They Raise (opens the original)
Read excerpt
A year ago I went to a health/bio startup event where all the founders pitching were women, all of the guest speakers were women, and 3 of the 4 investor judges were women, and get this, IT WASN’T BILLED AS A WOMEN’S EVENT! I thought, “wow, we did it!”Unfortunately it was a blip, not a trend. Last week I was invited to speak on AI as part of a larger event and after I accepted, they told me I’d be on the ‘women’s panel.’ Womp.Naseem Sayani <span
Stop Wasting Your TAM, SAM, and SOM Slide (opens the original)
Read excerpt
This is the third post in a three-part series on fundraising from generalist investors, which more founders building regulated technologies are doing these days because of our challenging fundraising environment.If generalists keep passing on you, you may be pitching them the same way you’d pitch someone who already knows the landscape. They don’t. I didn’t. I passed on regulated deals for years before I understood the space well enough to build a fund around it. Now it’s all I do.What changed w
"How does it work?" "It works great!" (opens the original)
Read excerpt
Thanks to everyone who reached out about last week’s post. Glad it resonated. This is the second post in a three-part series on fundraising from generalist investors, which more founders building regulated technologies are doing these days because of our challenging fundraising environment.If generalists keep passing on you, you may be pitching them the same way you’d pitch someone who already knows the landscape. They don’t. I didn’t. I passed on regulated deals for years before I understood th
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.